AxxessBio partners with Gennisium in the area of Neonatology

October 2020, Gennisium Pharma grants exclusive distribution rights to AxxessBio in Asia for Gencebok®.   Gencebok® (caffeine citrate) is indicated for the treatment of primary apnea of premature newborns. Caffeine citrate is the standard treatment for this conditon.   Apnea in preterm infants is common in babies born at less than 34 weeks’ gestation. This […]

AxxessBio and Dipharma provide solutions for metabolic diseases

October 2020, an exclusive agreement has been signed between AxxessBio and Dipharma  SA for Sapropterin and Miglustat in selected countries in Asia. Sapropterin and Miglustat are medicines for rare metabolic diseases. Sapropterin is indicated for Phenylketonuria and BH4 Deficiency. Miglustat is indicated for Type 1 Gaucher Disease and Niemann-Pick C Disease.   Metabolic diseases consist of disorders that disrupt […]

AxxessBio and Cycle Pharmaceuticals to introduce NITYR® (nitisinone) Tablets in Asia

On August 1st 2020 AxxessBio and Cycle Pharmaceuticals entered into an exclusive agreement for the distribution of NITYR® (nitisinone) tablets in Singapore, Thailand, Brunei, Philippines, Macau and Hong Kong. NITYR® does not have marketing authorization in these territories however it is being made available  through Name Patient Programs. These programs  differ country to country.   NITYR® (nitisinone) […]

AxxessBio announces an exclusive distribution agreement with ADIENNE for TEPADINA® (Thiotepa)

June 2020, AxxessBio announces an exclusive distribution agreement with ADIENNE (Lugano – Switzerland) for TEPADINA® (Thiotepa) for Singapore, Thailand, Malaysia, Vietnam, Philippines and Brunei. TEPADINA® 15mg and 100mg powder for concentrate for solution for infusion is used in combination with other chemotherapy medicinal products, as conditioning treatment prior to allogeneic or autologous hematopoietic stem cell transplantation in hematological […]

AxxessBio and BioScenergy enter into an exclusive distributorship in Inborn errors of metabolism

June 2018, AxxessBio and BioScenergy entered into an exclusive distribution agreement for BioScenergy’s Valens Metabolics range of products in selected countries in Asia.   These products are for Inborn Errors of Metabolism (IEM) which are rare genetic disorders characterised by abnormal chemical reactions in the body disrupting the normal food metabolism.   BioScenergy is based […]

Early Access Programs collaboration with myTomorrows

February 2018, a collaboration agreement was signed between AxxessBio and myTomorrows  to create awareness on the availability of non-registered products in Asia under the Early Access Programs, e.g., Named Patient Importation, as per local regulations, and for myTomorrows’s search engine for unregistered medicinal products.   The partnership between AxxessBio and myTomorrows allows healthcare providers and patients […]

AxxessBio and Green Cross partnership for Hunterase

June 2014, AxxessBio and GC Pharma (formerly Green Cross Corporation) signed an exclusive agreement to supply Hunterase in Malaysia.   Hunterase is an enzyme replacement therapy for Hunter Syndrome also known as Mucopolysaccharidosis II (MPS II). MPS II is a very rare inherited disease affecting mostly males. The individual is born with a missing enzyme that metabolizes […]

AxxessBio, a new office in Singapore

Since December 1st 2014, AxxessBio moved the regional head-office to a central location in Singapore, 36 Purvis Street, very near key landmarks like Raffles Hotel, Suntec City and the new Southbeach development.   This is a key milestone in the expansion of AxxessBio. With this move, AxxessBio has grown in its organization and added services […]